- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04354064
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
January 2, 2024 updated by: Washington University School of Medicine
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint.
Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Russell Pachynski, M.D.
- Phone Number: 314-286-2341
- Email: rkpachynski@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Sub-Investigator:
- Benjamin Tan, M.D.
-
Sub-Investigator:
- Ryan Fields, M.D.
-
Sub-Investigator:
- Aadel Chaudhuri, M.D., Ph.D.
-
Sub-Investigator:
- Sidharth Puram, M.D., Ph.D.
-
Sub-Investigator:
- Brian Van Tine, M.D., Ph.D.
-
Sub-Investigator:
- Re-I Chin, M.D.
-
Sub-Investigator:
- Varun Puri, M.D.
-
Sub-Investigator:
- Wade Thorstad, M.D.
-
Sub-Investigator:
- Hiram Gay, M.D.
-
Sub-Investigator:
- Koushik Das, M.D.
-
Sub-Investigator:
- Angela Hirbe, M.D., Ph.D.
-
Sub-Investigator:
- Imran Zoberi, M.D.
-
Sub-Investigator:
- Jose Zevallos, M.D., MPH
-
Sub-Investigator:
- Christopher Maher, Ph.D.
-
Contact:
- Russell Pachynski, M.D.
- Phone Number: 314-286-2341
- Email: rkpachynski@wustl.edu
-
Principal Investigator:
- Russell Pachynski, M.D.
-
Sub-Investigator:
- Peter Harris, Ph.D.
-
Sub-Investigator:
- Mackenzie Daly, M.D.
-
Sub-Investigator:
- Ha Dang, Ph.D.
-
Sub-Investigator:
- Paul Jones, B.A.
-
Sub-Investigator:
- James Hsieh, M.D., Ph.D.
-
Sub-Investigator:
- Zachary Smith, M.D.
-
Sub-Investigator:
- Eric Kim, M.D.
-
Sub-Investigator:
- Vivek Arora, M.D.
-
Sub-Investigator:
- Matthew Spraker, M.D., Ph.D.
-
Sub-Investigator:
- Cynthia Ma, M.D., Ph.D.
-
Sub-Investigator:
- Ricardo Ramirez, M.D.
-
Sub-Investigator:
- David Chen, M.D., Ph.D.
-
Sub-Investigator:
- Nicholas Semenkovich, M.D., Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
- This study will access data and specimens from patients who consented to specimen banks (approximately 3262 patients) There is a waiver of consent for this study regarding patient data banked under the tissue banks.
- Healthy donors will be consented prior to sample acquisition (approximately 100 patients)
Description
Inclusion Criteria:
- Eligible healthy donors will be at least 18 years of age.
Exclusion Criteria:
- Healthy donors younger than 18 years of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Healthy Donor Samples
|
Samples from Repository and Banking Studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from progression
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up
|
Through completion of study (estimated to be 6.5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as post-treatment ctDNA detection or RECIST 1.1 based radiographic progression
|
Through completion of study (estimated to be 6.5 years)
|
Disease-specific survival
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as death from cancer
|
Through completion of study (estimated to be 6.5 years)
|
Overall survival
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as death from any cause
|
Through completion of study (estimated to be 6.5 years)
|
Pathologic complete response rate
Time Frame: Through completion of study (estimated to be 6.5 years)
|
Through completion of study (estimated to be 6.5 years)
|
|
Locoregional failure
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as clinical or radiographic progression within the localized tumor/treatment area or regional lymph nodes
|
Through completion of study (estimated to be 6.5 years)
|
Distant-metastasis-free survival
Time Frame: Through completion of study (estimated to be 6.5 years)
|
-Defined as clinical or radiographic progression outside the localized tumor/treatment area and regional lymph nodes
|
Through completion of study (estimated to be 6.5 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Russell Pachynski, M.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2019
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
April 16, 2020
First Submitted That Met QC Criteria
April 16, 2020
First Posted (Actual)
April 21, 2020
Study Record Updates
Last Update Posted (Estimated)
January 3, 2024
Last Update Submitted That Met QC Criteria
January 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201903142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All of the individual participant data collected during the trial, after deidentification will be available for sharing with other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Viewpoint Molecular TargetingRecruitingMetastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, UvealUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States